Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1128/AAC.01061-20

http://scihub22266oqcxt.onion/10.1128/AAC.01061-20
suck pdf from google scholar
32661006!7449227!32661006
unlimited free pdf from europmc32661006    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32661006      Antimicrob+Agents+Chemother 2020 ; 64 (9): ä
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19 #MMPMID32661006
  • Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
  • Antimicrob Agents Chemother 2020[Aug]; 64 (9): ä PMID32661006show ga
  • To the best of our knowledge, there is no published study on the use of interferon beta-1a (IFN beta-1a) in the treatment of severe COVID-19. In this randomized clinical trial, the efficacy and safety of IFN beta-1a were evaluated in patients with severe COVID-19. Forty-two patients in the interferon group received IFN beta-1a in addition to the national protocol medications (hydroxychloroquine plus lopinavir-ritonavir or atazanavir-ritonavir). Each 44-mug/ml (12 million IU/ml) dose of interferon beta-1a was subcutaneously injected three times weekly for two consecutive weeks. The control group consisted of 39 patients who received only the national protocol medications. The primary outcome of the study was time to reach clinical response. Secondary outcomes were duration of hospital stay, length of intensive care unit stay, 28-day mortality, effect of early or late administration of IFN on mortality, adverse effects, and complications during the hospitalization. Between 29 February and 3 April 2020, 92 patients were recruited, and a total of 42 patients in the IFN group and 39 patients in the control group completed the study. As the primary outcome, time to the clinical response was not significantly different between the IFN and the control groups (9.7 +/- 5.8 versus 8.3 +/- 4.9 days, respectively, P = 0.95). On day 14, 66.7% versus 43.6% of patients in the IFN group and the control group, respectively, were discharged (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.05 to 6.37). The 28-day overall mortality was significantly lower in the IFN than the control group (19% versus 43.6%, respectively, P = 0.015). Early administration significantly reduced mortality (OR, 13.5; 95% CI, 1.5 to 118). Although IFN did not change the time to reach the clinical response, adding it to the national protocol significantly increased discharge rate on day 14 and decreased 28-day mortality. (This study is in the Iranian Registry of Clinical Trials under identifier IRCT20100228003449N28.).
  • |Adult[MESH]
  • |Aged[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Atazanavir Sulfate/*therapeutic use[MESH]
  • |Betacoronavirus/*drug effects/immunology/pathogenicity[MESH]
  • |COVID-19[MESH]
  • |Cardiovascular Diseases/drug therapy/immunology/mortality/virology[MESH]
  • |Comorbidity[MESH]
  • |Coronavirus Infections/*drug therapy/immunology/mortality/virology[MESH]
  • |Diabetes Mellitus/drug therapy/immunology/mortality/virology[MESH]
  • |Drug Administration Schedule[MESH]
  • |Drug Combinations[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Dyslipidemias/drug therapy/immunology/mortality/virology[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Intensive Care Units[MESH]
  • |Interferon beta-1a/*therapeutic use[MESH]
  • |Length of Stay[MESH]
  • |Lopinavir/*therapeutic use[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Neoplasms/drug therapy/immunology/mortality/virology[MESH]
  • |Pandemics[MESH]
  • |Patient Safety[MESH]
  • |Pneumonia, Viral/*drug therapy/immunology/mortality/virology[MESH]
  • |Ritonavir/*therapeutic use[MESH]
  • |SARS-CoV-2[MESH]
  • |Survival Analysis[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box